Peritoneal dialysis (PD) accounts for approximately 10% of the dialysis population worldwide. Major concern limiting long-term PD success is the loss of the peritoneal membrane function after prolonged exposure to dialysis solutions. The complement system is a major component of the innate immune system, which provides a first-line defense against pathogens. Uncontrolled activation of the complement system directly contributes to the pathophysiology of rare and common kidney diseases and to a growing number of nonrenal diseases. Here, we review currently available evidence of complement activation in patients treated with PD and its association with structural and functional alterations of the peritoneal membrane. Mainly, evidence point toward a local, intraperitoneal, production of complement molecules in response to PD exposure. Dialysis fluids, particularly glucose, play a role in complement activation and dysregulation leading to untoward PD-related pathophysiological processes such as peritoneal fibrosis, angiogenesis, and vasculopathy and, perhaps, encapsulating peritoneal fibrosis development. These findings could lead to further development and use of anticomplement therapeutics in PD patients to prevent membrane damage.
Van De LuijtgaardenMWJagerKJSegelmarkM, et al.Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period. Nephrol Dial Transplant2016; 31(1): 120–128.
2.
LiPKChowKMVan De LuijtgaardenMW, et al.Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol2017; 13(2): 90–103.
3.
MorelleJDevuystO. Water and solute transport across the peritoneal membrane. Curr Opin Nephrol Hypertens2015; 24(5): 434–443.
4.
MehrotraRDevuystODaviesSJ, et al.The current state of peritoneal dialysis. J Am Soc Nephrol2016; 27(11): 3238–3252.
5.
MorelleJSowAHautemN, et al.Interstitial fibrosis restricts osmotic water transport in encapsulating peritoneal sclerosis. J Am Soc Nephrol2015; 26(10): 2521–2533.
6.
FieldingCAJonesGWMcLoughlinRM, et al.Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity2014; 40(1): 40–50.
7.
LambieMRChessJSummersAM, et al.Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL fluid study. Nephrol Dial Transplant2016; 31(3): 480–486.
8.
WilliamsJDCraigKJTopleyN, et al.Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol2002; 13(2): 470–479.
9.
DevuystOMargettsPJTopleyN. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol2010; 21(7): 1077–1085.
10.
HtayHJohnsonDWWigginsKJ, et al.Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev2018; 10: CD007554.
11.
SchaeferBBartosovaMMacher-GoeppingerS, et al.Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis. Kidney Int2018; 94(2): 419–429.
12.
ThurmanJMRennerB. Dynamic control of the complement system by modulated expression of regulatory proteins. Lab Invest2011; 91(1): 4–11.
13.
HolersVM. Complement and its receptors: new insights into human disease. Annu Rev Immunol2014; 32: 433–459.
14.
RicklinDHajishengallisGYangK, et al.Complement: a key system for immune surveillance and homeostasis. Nat Immunol2010; 11(9): 785–797.
15.
MathernDRHeegerPS. Molecules great and small: the complement system. Clin J Am Soc Nephrol2015; 10(9): 1636–1650.
16.
HajishengallisGReisESMastellosDC, et al.Novel mechanisms and functions of complement. Nat Immunol2017; 18(12): 1288–1298.
17.
BartosovaMSchaeferBBermejoJL, et al.Complement activation in peritoneal dialysis-induced arteriolopathy. J Am Soc Nephrol2018; 29(1): 268–282.
18.
KittererDBieggerDSegererS, et al.Alteration of membrane complement regulators is associated with transporter status in patients on peritoneal dialysis. PLoS One2017; 12(5): e0177487.
19.
MizunoMSuzukiYHigashideK, et al.High levels of soluble C5b-9 complex in dialysis fluid may predict poor prognosis in peritonitis in peritoneal dialysis patients. PLoS One2017; 12(1): e0169111.
20.
RabyACColmontCSKift-MorganA, et al.Toll-like receptors 2 and 4 are potential therapeutic targets in peritoneal dialysis-associated fibrosis. J Am Soc Nephrol2017; 28(2): 461–478.
21.
ZavvosVBuxtonATEvansC, et al.A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent. Kidney Int2017; 92(4): 988–1002.
22.
SeiYMizunoMSuzukiY, et al.Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy. Mol Immunol2015; 65(2): 302–309.
23.
OliveiraEAraujoJEGomez-MeireS, et al.Proteomics analysis of the peritoneal dialysate effluent reveals the presence of calcium-regulation proteins and acute inflammatory response. Clin Proteomics2014; 11(1): 17.
24.
WenQZhangLMaoHP, et al.Proteomic analysis in peritoneal dialysis patients with different peritoneal transport characteristics. Biochem Biophys ResCommun2013; 38(3): 473–478.
25.
WangHYTianYFChienCC, et al.Differential proteomic characterization between normal peritoneal fluid and diabetic peritoneal dialysate. Nephrol Dial Transplant2010; 25(6): 1955–1963.
26.
RaaijmakersRPlukWSchroderCH, et al.Proteomic profiling and identification in peritoneal fluid of children treated by peritoneal dialysis. Nephrol Dial Transplant2008; 23(7): 2402–2405.
27.
TangSLeungJCChanLY, et al.Regulation of complement C3 and C4 synthesis in human peritoneal mesothelial cells by peritoneal dialysis fluid. Clin Exp Immunol2004; 136(1): 85–94.
28.
BarbanoGCappaFPrigioneI, et al.Peritoneal mesothelial cells produce complement factors and express CD59 that inhibits C5b-9-mediated cell lysis. Adv Perit Dial1999; 15: 253–257.
29.
ReddingiusRESchroderCHDahaMR, et al.Complement in serum and dialysate in children on continuous ambulatory peritoneal dialysis. Perit Dial Int1995; 15(1): 49–53.
30.
YoungGAKendallSBrownjohnAM. Complement activation during CAPD. Nephrol Dial Transplant1993; 8(12): 1372–1375.
31.
ReddingiusRESchroderCHDahaMR, et al.The serum complement system in children on continuous ambulatory peritoneal dialysis. Perit Dial Int1993; 13(3): 214–218.
32.
LamMFLeungJCTangCC, et al.Mannose binding lectin level and polymorphism in patients on long-term peritoneal dialysis. Nephrol Dial Transplant2005; 20(11): 2489–2496.
33.
ArboreGKemperCKolevM. Intracellular complement – the complosome – in immune cell regulation. Mol Immunol2017; 89: 2–9.
34.
PoppelaarsFFariaBGaya daCM, et al.The complement system in dialysis: a forgotten story?Front Immunol2018; 9: 71.
35.
GhoshPSahooRVaidyaA, et al.Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev2015; 36(3): 272–288.
36.
QinXGoldfineAKrumreiN, et al.Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes2004; 53(10): 2653–2661.
37.
AxelgaardEOstergaardJAThielS, et al.Diabetes is associated with increased autoreactivity of mannan-binding lectin. J Diabetes Res2017; 2017: 6368780.
38.
MizunoTMizunoMMorganBP, et al.Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrol Dial Transplant2011; 26(6): 1821–1830.
39.
MizunoMItoYHepburnN, et al.Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. J Immunol2009; 183(2): 1403–1412.
40.
MizunoTMizunoMImaiM, et al.Anti-C5a complementary peptide ameliorates acute peritoneal injury induced by neutralization of Crry and CD59. Am J Physiol Renal Physiol2013; 305(11): F1603–F1616.
41.
ClerbauxGFrancartJWallemacqP, et al.Evaluation of peritoneal transport properties at onset of peritoneal dialysis and longitudinal follow-up. Nephrol Dial Transplant2006; 21(4): 1032–1039.
42.
MillerFNHammerschmidtDEAndersonGL, et al.Protein loss induced by complement activation during peritoneal dialysis. Kidney Int1984; 25(3): 480–485.
43.
DanobeitiaJSDjamaliAFernandezLA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair2014; 7: 16.
44.
BoorPKoniecznyAVillaL, et al.Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol2007; 18(5): 1508–1515.
45.
TangZLuBHatchE, et al.C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol2009; 20(3): 593–603.
46.
ZhouXFukudaNMatsudaH, et al.Complement 3 activates the renal renin-angiotensin system by induction of epithelial-to-mesenchymal transition of the nephrotubulus in mice. Am J Physiol Renal Physiol2013; 305(7): F957–F967.
47.
Yanez-MoMLara-PezziESelgasR, et al.Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med2003; 348(5): 403–413.
48.
MoinuddinZSummersAVanDD, et al.Encapsulating peritoneal sclerosis – a rare but devastating peritoneal disease. Front Physiol2014; 5: 470.
49.
MizunoMItoYMizunoT, et al.Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats. Am J Physiol Renal Physiol2012; 302(10): F1245–F1251.
50.
IguchiDMizunoMSuzukiY, et al.Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rats pretreated with methylglyoxal. Am J Physiol Renal Physiol2018; 315(6): F1732–F1746.
51.
BazarganiFAlbrektssonAYahyapourN, et al.Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation. Perit Dial Int2005; 25(4): 394–404.
52.
BazarganiFRotherRPBraideM. The roles of complement factor C5a and CINC-1 in glucose transport, ultrafiltration, and neutrophil recruitment during peritoneal dialysis. Perit Dial Int2006; 26(6): 688–696.
53.
Lopes BarretoDCoesterAMStruijkDG, et al.Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?Perit Dial Int2013; 33(5): 529–537.
54.
Lopes BarretoDStruijkDGKredietRT. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis. Am J Kidney Dis2015; 65(5): 748–753.
55.
RicklinDMastellosDCReisES, et al.The renaissance of complement therapeutics. Nat Rev Nephrol2018; 14(1): 26–47.
56.
VychytilAHerzogRProbstP, et al.A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. Kidney Int2018; 94(6): 1227–1237.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
